Promedior, Inc.
http://www.promedior.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Promedior, Inc.
Another IPF Drug Failure As Galecto Therapy Suffers Mid-Stage Flop
Galecto’s decision to discontinue its idiopathic pulmonary fibrosis candidate after disappointing Phase IIb results represents the latest in a number of mid/late-stage failures to treat the disease.
Boehringer Bids To Go Beyond Slowing IPF
The family-owned German group is the market leader in idiopathic pulmonary fibrosis with Ofev but the big-selling drug has significant side effects and only slows, but does not stop, the progression of the disease. It is hoping that the Phase III-ready compound BI 1015550 will offer a significant improvement.
COVID-19 Accounts For Most Of 2020’s Pharma Pipeline Growth
The impact of the coronavirus pandemic on the size of the pharma R&D pipeline in 2020 could be felt in a number of ways.
Finance Watch: VC Mega-Rounds Fund Wide Array, From Respiratory To Rare Diseases
Private Company Edition: China-focused Nuance Pharma led recent venture capital deals with a $181m series D round, RayzeBio closed a $105m series B and SciNeuro launched with $100m plus other notable rounds from Edgewise, Reneo, BioAge and others.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice